<PAGE>

                 U.S. SECURITIES AND EXCHANGE COMMISSION
                          WASHINGTON, D.C. 20549
                                     
                                 FORM 10-Q

/X/  Quarterly Report Pursuant to Section 13 or 15(d) of the Securities 
Exchange Act of 1934 for the Period Ended June 30, 1998.

                                      or

/ /  Transition Report Pursuant to Section 13 or 15(d) of the Securities 
Exchange Act of 1934 for the Transition Period From __________ to ____________.

     Commission file number 0-27436



                         TITAN PHARMACEUTICALS, INC.
          (Exact name of registrant as specified in its charter)

               DELAWARE                               94-3171940
               --------                               ----------
    (State or Other Jurisdiction of                  (IRS Employer
     Incorporation or Organization)                Identification No.)

    400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO, CALIFORNIA 94080
    ------------------------------------------------------------------------
           (Address of Principal Executive Offices including zip code)
                                     
                               (650) 244-4990
                               --------------
            (Registrant's Telephone Number, Including Area Code)


Indicate by check mark whether the registrant (1) has filed all reports 
required to be filed by Section 13 or 15(d) of the Exchange Act during the 
preceding 12 months (or for such shorter period that the registrant was 
required to file such reports), and (2) has been subject to such filing 
requirements for the past 90 days.  Yes  _X_    No  ___

There were 13,123,508 shares of the Registrant's Common Stock issued and 
outstanding on August 7, 1998.

<PAGE>
                            TITAN PHARMACEUTICALS, INC.
                                 INDEX TO FORM 10-Q


PART I.   FINANCIAL INFORMATION                                           PAGE
                                                                          ----

          Item 1.  Condensed Consolidated Financial Statements 
            (unaudited)

          Condensed Consolidated Balance Sheets  
            June 30, 1998 and December 31, 1997. . . . . . . . . . . . . . .3

          Condensed Consolidated Statements of Operations
            Three months and six months ended June 30, 1998
            and 1997 and period from commencement of 
            operations (July 25, 1991) to June 30, 1998. . . . . . . . . . .4

          Condensed Consolidated Statements of Cash Flows
            Six months ended June 30, 1998 and 1997 and
            period from commencement of operations 
            (July 25, 1991) to June 30, 1998 . . . . . . . . . . . . . . . .5

          Notes to Condensed Consolidated Financial 
            Statements - June 30, 1998 . . . . . . . . . . . . . . . . . . .7

          Item 2.  Management's Discussion and Analysis 
            or Plan of Operations. . . . . . . . . . . . . . . . . . . . . .9

PART II.  OTHER INFORMATION

          Item 6.  Exhibits and Reports on Form 8-K. . . . . . . . . . . . 11

SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12


                                       2

<PAGE>
Part I. Financial Information

                            TITAN PHARMACEUTICALS, INC.
                           (a development stage company)
                        CONDENSED CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
                                                       June 30,    December 31,
                                                         1998          1997
                                                      (unaudited)    (Note A)
                                                      -----------  ------------
<S>                                                   <C>          <C>
Assets
Current assets
     Cash and cash equivalents                        $16,787,071  $24,386,872
     Short-term investments                               500,000      500,000
     Prepaid expenses and other current assets            160,558       58,937
     Other receivables                                        -        371,793
                                                      -----------  ------------
          Total current assets                         17,447,629   25,317,602
Furniture and equipment, net                              228,633      253,723
Other assets                                               22,898       22,898
                                                      -----------  ------------
                                                      $17,699,160  $25,594,223
                                                      -----------  ------------
                                                      -----------  ------------
Liabilities and Stockholders' Equity
Current Liabilities
     Accounts payable                                    $642,802     $815,449
     Accrued legal fees                                    60,991      244,486
     Accrued sponsored research                           135,058       65,500
     Accrued payroll and related                          163,105      257,751
     Accrued professional and accounting fees              40,000      100,000
     Other accrued liabilities                            105,885      192,487
                                                      -----------  ------------
          Total current liabilities                     1,147,841    1,675,673
Commitments
Minority interest - Series B preferred stock of 
   Ingenex, Inc.                                        1,241,032    1,241,032
Guaranteed security value (Note 2)                                   5,500,000
Stockholders' Equity
     Preferred stock, at amounts paid in                5,000,000    5,000,000
     Common stock, at amounts paid in                  52,294,219   49,622,796
     Additional paid-in capital                         6,521,353    6,521,353
     Deferred compensation                               (372,460)    (458,340)
     Deficit accumulated during the development 
      stage                                           (48,132,825) (43,508,291)
                                                      -----------  ------------
          Total stockholders' equity                   15,310,287   17,177,518
                                                      -----------  ------------
                                                      $17,699,160  $25,594,223
                                                      -----------  ------------
                                                      -----------  ------------
</TABLE>

          Note A:  The balance sheet at December 31, 1997 has been derived from
          the audited financial statements at that date but does not include all
          of the information and footnotes required by generally accepted
          accounting principles for complete financial statements.

              See Notes to Condensed Consolidated Financial Statements

                                       3

<PAGE>
<TABLE>
<CAPTION>

                                                         TITAN PHARMACEUTICALS, INC.
                                                        (a development stage company)
                                                 CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
                                                                 (unaudited)
                                                                                                                    COMMENCEMENT
                                                        THREE MONTHS ENDED JUNE 30,   SIX MONTHS ENDED JUNE 30,    OF OPERATIONS
                                                        ---------------------------   -------------------------    (JULY 25, 1991)
                                                           1998           1997            1998         1997        TO JUNE 30, 1998
                                                        -----------    -----------    -----------   ------------   ----------------
<S>                                                     <C>            <C>            <C>           <C>            <C>
License and grant revenue                               $     -        $   111,483    $    -        $    147,745     $ 17,898,281

Costs and expenses:
     Research and development                             1,465,540      2,643,240      3,151,780      4,817,975      40,042,096
     Acquired in-process research and development             -              -                         9,500,000      10,186,000
     General and administrative                             973,909      1,626,973      2,003,529      2,963,891      20,345,478
                                                        -----------    -----------    -----------   ------------    ------------
          Total costs and expenses                        2,439,449      4,270,213      5,155,309     17,281,866      70,573,574
                                                        -----------    -----------    -----------   ------------    ------------
          Loss from operations                           (2,439,449)    (4,158,730)    (5,155,309)   (17,134,121)    (52,675,293)
Other income (expense):
     Equity in loss of Ansan Pharmaceuticals, Inc.            -           (221,785)           -         (501,824)     (2,046,939)
     Gain on sale of technology                               -          8,513,884            -        8,513,884       8,361,220
     Interest income                                        225,074        147,378        488,893        319,313       2,326,054
     Interest expense                                         -            (63,670)           (87)      (138,741)     (4,389,774)
     Loss on sale of fixed assets                           (13,431)         -            (13,431)           -           (13,431)
     Other income (expense)                                    (226)         -             55,400            -           260,424
                                                        -----------    -----------    -----------   ------------    ------------
          Other income (expense) - net                      211,417      8,375,807        530,775      8,192,632       4,497,554
                                                        -----------    -----------    -----------   ------------    ------------
Income (loss) before minority interest                   (2,228,032)     4,217,077     (4,624,534)    (8,941,489)    (48,177,739)
Minority interest in losses of subsidiaries                   -              -              -              -              44,914
Net income (loss)                                       $(2,228,032)   $ 4,217,077    $(4,624,534)   $(8,941,489)   $(48,132,825)

Deemed dividend upon conversion of preferred stock            -              -              -              -          (5,431,871)
                                                        -----------    -----------    -----------   ------------    ------------

Net income (loss) attributable to common stockholders   $(2,228,032)   $ 4,217,077    $(4,624,534)   $(8,941,489)   $(53,564,696)
                                                        -----------    -----------    -----------   ------------    ------------
                                                        -----------    -----------    -----------   ------------    ------------
Basic and diluted earnings (net loss) per common share  $     (0.17)   $      0.32    $     (0.35)   $     (0.69)
                                                        -----------    -----------    -----------   ------------
                                                        -----------    -----------    -----------   ------------
Shares used in computing basic earnings (net loss) 
 per share                                                13,108,230     13,046,102     13,093,516     12,971,902
                                                        -----------    -----------    -----------   ------------
                                                        -----------    -----------    -----------   ------------

Shares used in computing diluted earnings per share                     13,242,099
                                                                       ----------- 
                                                                       ----------- 
</TABLE>

             See Notes to Condensed Consolidated Financial Statements

                                       4

<PAGE>
                            TITAN PHARMACEUTICALS, INC.
                           (a development stage company)
                  CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (unaudited)
<TABLE>
<CAPTION>
                                                                                     PERIOD FROM
                                                                                    COMMENCEMENT
                                                      SIX MONTHS ENDED JUNE 30,     OF OPERATIONS
                                                      ---------------------------   (JULY 25, 1991)
                                                          1998           1997       TO MARCH 31,1998
                                                      ------------   ------------   ----------------
<S>                                                   <C>            <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss                                              $(4,624,534)   $(8,941,489)    $(48,132,825)
Adjustments to reconcile net loss to net cash used
  in operating activities:
   Depreciation and amortization expense                  145,054        245,576        1,593,748
   Issuance of common stock to acquire technology             -        5,500,000        5,500,000
   Payment of guaranteed security value                (3,044,409)           -         (3,044,409)
   Loss (gain) on sale of assets                           14,105       (218,654)          14,105
   Accretion of discount on indebtedness                      -              -          2,290,910
   Equity in loss of Ansan Pharmaceuticals, Inc.              -          501,825        2,046,940
   Other                                                      -              -            (35,653)
   Issuance of common stock to acquire                                              
       minority interest of Theracell, Inc.                   -              -            686,000
   Changes in operating assets and liabilities:                                     
     Prepaid expenses and other current assets           (101,621)       (22,765)        (160,558)
     Receivable from Ansan Pharmaceuticals, Inc.              -          (71,419)             -  
     Other receivables                                    371,793            -                -  
     Other assets                                             -          152,564          (27,863)
     Accounts payable                                    (172,647)       420,491          966,992
     Accrued license fee                                      -        2,000,000              -
     Other accrued liabilities                           (355,185)       390,366          905,455
                                                      -----------    -----------     ------------
Net cash used in operating activities                  (7,767,444)       (43,505)     (37,397,158)
                                                      -----------    -----------     ------------
                                                                                                                
CASH FLOWS FROM INVESTING ACTIVITIES                                                
Purchase of furniture and equipment                       (71,189)       (51,718)      (1,222,412)
Proceeds from sale of furniture and equipment              23,000            -             23,000
Purchase of short-term  investments                           -         (100,000)     (59,782,493)
Proceeds from sale of short-term investments                  -       12,600,000       59,282,493
Issuance of debenture to Ansan                                                      
    Pharmaceuticals, Inc.                                     -       (1,000,000)   
Effect of deconsolidation of                                                        
    Ansan Pharmaceuticals, Inc.                               -              -           (135,934)
                                                      -----------    -----------     ------------
Net cash (used in)/provided by investing activities       (48,189)    11,448,282       (1,835,346)
                                                      -----------    -----------     ------------
</TABLE>

             See Notes to Condensed Consolidated Financial Statements

                                       5

<PAGE>
                            TITAN PHARMACEUTICALS, INC.
                           (a development stage company)
                  CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (unaudited)

<TABLE>
<CAPTION>
                                                                                      PERIOD FROM
                                                                                      COMMENCEMENT
                                                       SIX MONTHS ENDED JUNE 30,     OF OPERATIONS
                                                      ---------------------------   (JULY 25, 1991)
                                                          1998           1997       TO MARCH 31,1998
                                                      ------------   ------------   ----------------
<S>                                                   <C>            <C>            <C>
CASH FLOWS FROM FINANCING ACTIVITIES                                                
Issuance of common stock                                  215,832          2,998       30,244,606
Deferred financing costs                                      -           46,349         (713,899)
Issuance of preferred stock                                   -              -         17,601,443
Issuance of preferred stock - Novartis                        -              -          5,000,000
Proceeds from notes and advances payable                      -              -          2,681,500
Repayment of notes payable                                    -              -         (1,441,500)
Proceeds from Ansan bridge financing                          -              -          1,425,000
Proceeds from Titan Pharmaceuticals, Inc. and                                       
    Ingenex, Inc. bridge financing                            -              -          5,250,000
Repayment of Titan Pharmaceuticals, Inc. and                                        
    Ingenex, Inc. bridge financing                            -              -         (5,250,000)
Payments of principle under capital lease obligation          -         (127,462)        (633,766)
Proceeds from capital lease bridge financing                  -              -            658,206
Proceeds from Ingenex, Inc. technology financing              -              -          2,000,000
Principal payments on Ingenex, Inc. technology financing      -       (1,289,313)      (2,000,000)
Increase in minority interest from issuances of                                     
    preferred stock by Ingenex, Inc.                          -              -          1,241,032
Issuance of common stock by subsidiaries                      -              -            173,652
Loss (gain) on disposal of assets                             -              -           (216,699)
                                                      -----------    -----------     ------------
Net cash provided by/(used in) financing activities       215,832     (1,367,428)      56,019,575
                                                      -----------    -----------     ------------

Net (decrease)/increase in cash and cash equivalents   (7,599,801)    10,037,349       16,787,071
Cash and cash equivalents, beginning of period         24,386,872      1,376,532              -  
                                                      -----------    -----------     ------------
Cash and cash equivalents, end of period              $16,787,071    $11,413,881     $ 16,787,071
                                                      -----------    -----------     ------------
                                                      -----------    -----------     ------------
                                                                                    
Supplemental cash flow disclosure                                                   
Interest paid                                            $     87       $138,741     $  1,393,396
                                                      -----------    -----------     ------------
                                                      -----------    -----------     ------------
</TABLE>

             See Notes to Condensed Consolidated Financial Statements

                                       6

<PAGE>

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

THE COMPANY AND ITS SEVERAL DEVELOPMENT STAGE SUBSIDIARIES
   
     Titan Pharmaceuticals, Inc. (the "Company" or "Titan"), was incorporated 
in February 1992 in the State of Delaware.  Titan is a biopharmaceutical 
company developing proprietary therapeutics for the treatment of central 
nervous system disorders, cancer and other serious and life-threatening 
diseases.  Titan conducts a portion of its operations through three 
development stage biotechnology companies: Ingenex, Inc. ("Ingenex"), 
Theracell, Inc. ("Theracell") and ProNeura, Inc. ("ProNeura"), collectively, 
(the "Operating Companies").  Trilex Pharmaceuticals, Inc. ("Trilex") was 
incorporated in May 1996, as a wholly owned subsidiary of the Company, to 
engage in the development of cancer therapeutic vaccines utilizing 
anti-idiotypic antibody technology.  In August 1997, Trilex was merged (the 
"Trilex Merger") with and into Titan.

     INGENEX, INC.    

     Ingenex was incorporated in July 1991 and reincorporated in June 1992. 
It is engaged in the development of gene-based therapeutics. In June 1997, 
Ingenex sold its GSX System (the "GSX Sale"), a research technology, and 
certain fixed assets to Pharmaceutical Product Development, Inc. ("PPD") for 
$8,722,500 in cash and the assumption of certain capital lease liabilities 
and recognized a gain of $8,361,220.  At June 30, 1998, the Company owned 81% 
of Ingenex.

     THERACELL, INC.
   
     Theracell was incorporated in November 1992 to engage in the development 
of novel treatments for various neurologic disorders through the 
transplantation of neural cells and neuron-like cells directly into the 
brain. At June 30, 1998, the Company owned 98% of Theracell.  

     PRONEURA, INC.

     ProNeura was incorporated in October 1995 to engage in the development 
of cost effective, long term treatment solutions to neurologic and 
psychiatric disorders through an implantable drug delivery system.  At June 
30, 1998, the Company owned 79% of ProNeura.

BASIS OF PRESENTATION 
   
     The accompanying unaudited condensed consolidated financial statements 
include the accounts of Titan and its majority owned subsidiaries after 
elimination of all significant inter-company accounts and transactions.  
These financial statements have been prepared in accordance with generally 
accepted accounting principles for interim financial information and with the 
instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, 
they do not include all of the information and footnotes required by 
generally accepted accounting principles for complete financial statements.  
In the opinion of management, all adjustments (consisting of normal recurring 
accruals) considered necessary for a fair presentation have been included.  
Operating results for the six-month period ended June 30, 1998 are not 
necessarily indicative of the results that may be expected for the year ended 
December 31, 1998.  These financials should be read in conjunction with the 
audited consolidated financial statements and footnotes thereto included in 
the Titan Pharmaceuticals, Inc. annual report on Form 10-K for the year ended 
December 31, 1997.
   

2. GUARANTEED SECURITY VALUE

      In January 1997, the Company entered into an exclusive license 
agreement with Hoechst Marion Roussel, Inc. ("HMRI").  The license agreement 
gave the Company a worldwide license to HMRI's patent rights and know-how 
related to the antipsychotic agent Iloperidone-TM-.  Pursuant to the license, 
the Company paid, during 1997, an up-front license fee of $9,500,000, 
consisting of:  (i) $4,000,000 in cash and (ii) $5,500,000 through the 
issuance 594,595 shares of common stock (the "HMRI Shares".)  The Company was 
obligated to pay to HMRI the difference between $5,500,000 and the net 
proceeds received by HMRI upon sale of the above mentioned 

                                       7

<PAGE>

common stock.  Accordingly, the Company had classified the entire $5,500,000 
as a non-current liability under the heading Guaranteed Security Value in the 
accompanying December 31, 1997 balance sheet. In February 1998, HMRI sold the 
HMRI Shares for net proceeds of approximately $2,456,000. Accordingly, in 
March 1998, the Company paid to HMRI approximately $3,044,000, which was 
deducted from Guaranteed Security Value balance.  The remaining balance of 
$2,456,000 was transferred to stockholders' equity.

3. CHANGES IN ACCOUNTING STANDARDS

     As of January 1, 1998, the Company adopted Statement of Financial 
Accounting Standards No. 130, "Reporting Comprehensive Income" ("SFAS No. 
130").  SFAS No. 130 establishes new rules for the reporting and display of 
comprehensive income and its components; however, the adoption of this 
statement has no impact on the Company's net income/loss or stockholders' 
equity.  During the three months ended June 30, 1998 and 1997 and the six 
months ended June 30, 1998 and 1997, the Company's comprehensive income/loss 
was the same as the Company's net income/loss for such periods.

                                       8

<PAGE>

ITEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

     The following discussion contains certain forward-looking statements, 
within the meaning of the "safe harbor" provisions of the Private Securities 
Litigation Reform Act of 1995, the attainment of which involves various risks 
and uncertainties.  Forward-looking statements may be identified by the use 
of forward-looking terminology such as "may", "will", "expect", "believe", 
"estimate", "anticipate", "continue" or similar terms, variations of those 
terms or the negative of those terms.  The Company's actual results may 
differ materially from those described in these forward-looking statements 
due to, among other factors, the results of ongoing research and development 
activities and preclinical testing, the results of clinical trials and the 
availability of additional financing through corporate partnering 
arrangements or otherwise.

RESULTS OF OPERATIONS

     Since its inception, the Company's efforts have been principally devoted 
to research and development, including human clinical trials, as well as to 
acquiring licenses and technologies, raising capital and securing patent 
protection.  At June 30, 1998, the Company had an accumulated deficit of 
approximately $48,133,000, resulting from expenditures for research and 
development and general and administrative activities including professional 
fees.

     There were no revenues for the three months ended June 30, 1998 (the 
"1998 quarter") and for the six months ended June 30, 1998 (the "1998 six 
months"). Total revenues for the three months ended June 30, 1997 (the "1997 
quarter") were approximately $111,000, and total revenues for the six months 
ended June 30, 1997 (the "1997 six months") were approximately $148,000.  
Revenue earned during both the 1997 six months and quarter was earned 
pursuant to US government grants.

     Research and development expenses for the 1998 quarter were 
approximately $1,466,000 compared to $2,643,000 for the 1997 quarter, a 
decrease of 45%.  For the 1998 six months, research and development expenses 
were $3,152,000 compared to $4,818,000 for the 1997 six months, a decrease of 
35%.  The 1997 six months and the 1997 quarter include expenditures related 
to a research technology, which was subsequently sold by the Company in June 
1997.  The 1997 six months and the 1997 quarter also include expenditures 
related to the development of Iloperidone, which is now being funded by 
Novartis Pharma AG pursuant to the partnering agreement (the "Novartis 
Sublicense") establish by Titan and Novartis in November 1997.

     The results for the 1997 six months also include a non-recurring, 
acquired in-process research and development charge of $9,500,000 related to 
the acquisition of Iloperidone.  

     General and administrative expenses for the 1998 quarter were 
approximately $974,000 compared to $1,627,000 for the 1997 quarter, a 
decrease of 40%.  For the 1998 six months, general and administrative 
expenses were $2,004,000 compared to $2,964,000 for the 1997 six months, a 
decrease of 32%.  The 1997 six months includes expenditures related to a 
former subsidiary, which was merged with and into the Company in August 1997.

     Other income for the 1997 quarter and the 1997 six months includes a 
gain of approximately $8,514,000 from the sale of GSX, a research technology 
developed by Ingenex, and certain fixed assets.  Interest income was 
approximately $225,000 during the 1998 quarter compared to $147,000 during 
the 1997 quarter. For the 1998 six months, interest income was $489,000 
compared to $319,000 for the 1997 six months.  Interest expense decreased to 
approximately $100 during the 1998 six months from $139,000 during the 1997 
six months.  There was no interest expense for the 1998 quarter compared to 
$64,000 for the 1997 quarter. Other income for the 1997 six months also 
includes losses of approximately $502,000 representing the Company's share of 
Ansan Pharmaceutical's losses.  The Company's share of Ansan's losses for the 
1997 quarter was $222,000.


                                       9

<PAGE>

LIQUIDITY AND SOURCES OF CAPITAL

     The Company has funded its operation from inception primarily through 
private placements of its securities, as well as the IPO.  During 1997, the 
Company also received approximately $25,861,000 from up-front license fees 
relating to the Novartis Sublicense and the sale of a research technology.

     In March 1998, the Company paid to HMRI approximately $3,044,000 (the 
difference between the net proceeds received by HMRI, upon the sale of the 
HMRI Shares in February 1998, and the $5,500,000 guaranteed value of the HMRI 
Shares when issued.)  As the Company classified the $5,500,000 as guaranteed 
security value, the HMRI Shares had not been included in stockholders' 
equity.  Upon the payment to HMRI, approximately $2,456,000 was credited to 
stockholders' equity.

     Titan has entered into various agreements with research institutions, 
universities, and other entities for the performance of research and 
development activities and for the acquisition of licenses related to those 
activities.  The aggregate commitments the Company has under these 
agreements, including minimum license payments, for the next 12 months is 
approximately $2,000,000.  Certain of the licenses provide for the payment of 
royalties by the Company on future product sales, if any.  In addition, in 
order to maintain license and other rights while products are under 
development, the Company must comply with customary licensee obligations, 
including the payment of patent related costs and meeting project-funding 
milestones.

     The Company expects to continue to incur substantial additional 
operating losses from costs related to continuation and expansion of research 
and development, clinical trials, and increased administrative and fund 
raising activities over at least the next several years.  While the Company 
has sufficient working capital to sustain planned operations for a period 
greater than 12 months, the Company may seek additional financing sooner, 
depending on numerous factors including, but not limited to, the progress of 
the Company's research and development programs, the results of clinical 
studies, technological advances, determinations as to the commercial 
potential of the Company's products, and the status of competitive products.  
In May 1998, the Company negotiated a $5,000,000 bank line of credit.  In 
addition, certain expenditures will be dependent on the establishment of 
collaborative relationships with other companies, the availability of 
financing, and other factors.  In any event, the Company anticipates that it 
will require substantial additional financing in the future.  There can be no 
assurance as to the availability or terms of any required additional 
financing, when and if needed.


                                       10

<PAGE>

                                     PART II

ITEM 6.   EXHIBITS AND REPORTS ON FORM 8-K
          --------------------------------

          (a)            Exhibits

               27.1      Financial Data Schedule



          (b)  Reports on Form 8-K
          
               No reports on Form 8-K were filed during the six months ended
               June 30, 1998.




                                       11

<PAGE>

                                   SIGNATURES


     In accordance with the requirements of the Exchange Act, the registrant 
caused this report to be signed on its behalf by the undersigned, thereunto 
duly authorized.
   


                                   TITAN PHARMACEUTICALS, INC.


          August 14, 1998          By: /s/Louis R. Bucalo
                                       --------------------------------------
                                       Louis R. Bucalo, M.D., President and 
                                       Chief Executive Officer

          August 14, 1998          By: /s/Robert E. Farrell
                                       --------------------------------------
                                       Robert E. Farrell, Chief Financial 
                                       Officer